If you have been reading about preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-30. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Spondyloepiphyseal dysplasia congenita is one of a spectrum of skeletal disorders caused by mutations in the COL2A1 gene. The protein made by this gene forms type II collagen, a molecule found mostly in cartilage and in the clear gel that fills the eyeball (the vitreous). Type II collagen is essential for the normal development of bones and other connective tissues. Mutations in the COL2A1 gene interfere with the assembly of type II collagen molecules, which prevents bones from developing properly and causes the signs and symptoms of this condition. Spondyloepiphyseal dysplasia congenita is inherited in an autosomal dominant pattern, which means one copy of the altered gene is sufficient to cause the disorder.
== History == Mirtazapine was first synthesized at Organon and published in 1989, was first approved for use in major depressive disorder in the Netherlands in 1994, and was introduced in the United States in 1996 under the brand name Remeron.
The casein to whey protein ratio in donkey milk was lower compared to the value in cow milk. Non-protein nitrogen (NPN) accounts for an average of 16% of total nitrogen in donkey milk, which is close to values reported for human milk (20%) but higher than those of domestic ruminants (5%). The amino acid profile of the donkey milk proteins shows a very similar percentage of essential amino acids (36.7 to 38.2 g amino acid /100 g protein) than in human milk proteins (40.7 g amino acid /100 g protein).
2019: Micheal Anak Garing, a Malaysian hanged on 22 March 2019 for the murder of a construction worker during a series of armed robberies in 2010. 2025: Iskandar bin Rahmat, a former police officer hanged on 5 February 2025 for the 2013 Kovan double murders. 2025: Eric Teo Ghim Heng, a former property agent hanged on 16 April 2025 for the murder of his wife and their daughter in 2017, which became known as the Woodlands double murders.
Sources: en.wikipedia.org
=== Causes === Scholars have pointed to materialist and ideational reasons for the end of the Cold War. Materialists emphasize Soviet economic difficulties (such as economic stagnation and sovereign debt), whereas ideationalists argue that the worldviews and personas of Gorbachev and Reagan mattered. Ideationalists point to a Gorbachev and Reagan's mutual desire to abolish nuclear weapons, as well as Gorbachev's perceptions of foreign policy. To this end, Gorbachev's re-conceptualization of security—emphasizing mutual restraint, political choice, and non-coercion—proved central to ending the Cold War. Historian David Reynolds points out that the Soviet bloc's deepening technology gap was a structural cause in its own right. One materialist example Reynolds identified was the Soviet personal computer, the Agat, which during the mid-1980s remained an inferior copy of the outdated Apple II; meanwhile, Gorbachev's own informatizatsiia initiative aimed at just 1.3 million schoolroom computers by 1995, against the three million already in American classrooms by 1985 alone. Similar technological deficiencies plagued East Germany to the extent that historian Charles Maier characterized the late-1980s GDR economy as caught in "a race between computers and collapse." Concomitantly, additional ideational arguments—beyond the aforementioned influence of Gorbachev and Reagan—can be discerned from the example of Western Europe, where the decisive contribution lay less in diplomacy than in demonstration, according to historian John W. Young.
In July, the chief administrator of the Environmental Protection Agency announced rescinding of the 2009 endangerment finding, which concluded that planet-warming greenhouse gases pose a threat to public health. (The endangerment finding is the scientific determination that underpins the federal government's legal authority to combat climate change.) In concurrence with the attempt to rollback the endangerment finding, Trump's Department of Energy released an assessment titled A Critical Review of Impacts of Greenhouse Gas Emissions on the U.S. Climate. The report was assembled by five climate science contrarians and was heavily criticized for cherry-picked evidence, falsehoods, and distortions. The Union of Concerned Scientists called it "deeply flawed [and] anti-science". Climate scientist Andrew Dessler called it "a mockery of science". On February 12, 2026, the EPA formally rescinded the Endangerment Finding. In August 2025, the Bureau of Land Management initiated a review of offshore wind energy regulations and revised its rules to favor fossil fuel production over renewables. On September 23, 2025, Trump told the United Nations General Assembly that climate change is "the greatest con job ever perpetrated on the world", that scientific predictions "were made by stupid people", and that renewable energy is a "scam". In October 2025, the Department of Energy cancelled 321 clean energy grants, totaling $7.56 billion, issued in the Biden administration.
=== Consumer healthcare === GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh, Macleans and Sensodyne toothpastes. GSK also previously owned the Lucozade and Ribena brands of soft drinks, but they were sold in 2013, to Suntory for £1.35bn. Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements. In March 2014, it recalled Alli, an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints. On 18 July 2022, GSK formally spun off its consumer healthcare business as a separate entity, Haleon.
Ions can be created in an electric glow discharge. A glow discharge is a plasma formed by the passage of electric current through a low-pressure gas. It is created by applying a voltage between two metal electrodes in an evacuated chamber containing gas. When the voltage exceeds a certain value, called the striking voltage, the gas forms a plasma. A duoplasmatron is a type of glow discharge ion source that consists of a hot cathode or cold cathode that produces a plasma that is used to ionize a gas. They can produce positive or negative ions. They are used for secondary ion mass spectrometry, ion beam etching, and high-energy physics.
== Use and effects == 4-HO-EPT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved). Subsequently, however, an assumed prodrug of 4-HO-EPT, 4-AcO-EPT, has emerged as a novel designer drug, and has been said based on online anecdotal reports to have a dose of 20 to 30 mg orally.
Sources: en.wikipedia.org
=== Ultrasound === Hepatomegaly is consistently identified with an abdominal ultrasound; however, it is also commonly found in diabetic cats without hypersomatotropism. Other findings from an abdominal ultrasound include: renomegaly, pelvic dilation, an enlarged pancreas, splenomegaly and bilateral adrenomegaly. The size of the adrenal glands can be useful in diagnosis, studies have found that the size of the adrenal gland in diabetic cats without hypersomatotropism does not differ significantly from non-diabetic cats; however, adrenomegaly is not pathognomonic to hypersomatotropism and can occur with other conditions in cats such as pituitary-dependent hypercortisolism.
=== Middle East === A Taco Bell opened in the United Arab Emirates in November 2008 in Dubai at the Dubai Mall. A fourth UAE location was also planned for Bawadi Mall in the city of Al Ain. The locations at Dubai Mall, Deira City Centre, and Mirdif City Centre have all closed and Taco Bell has completely pulled out of the Emirati market. Taco Bell is still open in Kuwait and has not been pulled out ever since from the Kuwaiti market, as the chain is franchised in this region by Kout Food Group.
=== Legal status === Rusfertide was approved for medical use in the United States in August 2026. The US Food and Drug Administration (FDA) granted the application for rusfertide priority review. The FDA granted the approval of Mimrylo to Takeda Pharmaceuticals America.
It aids in normal mammary gland development. It is necessary for maintenance of the mammary bud cells. Loss of PTHrP or its receptor causes the mammary bud cells to change back into epidermal cells. In lactation, it may regulate the mobilization and transfer of calcium to the milk in conjunction with the calcium sensing receptors, as well as placental transfer of calcium.
=== Novel genes === In general, genes without detectable homologs can be summarized under the term novel genes. These genes can also be called orphan genes, or — more precisely — species-/lineage-specific genes. The term de novo describes a specific subclass of novel genes, namely genes emerging from non-genic sequences. A key caveat is that orphan (taxonomically restricted) genes are heterogeneous in origin and age—lack of detectable homology can reflect multiple processes (including horizontal transfer, transposable element domestication, overprinting, or extreme divergence) and is not, by itself, evidence of de novo origin.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.